TAIHO PHARMACEUTICAL CO., LTD.
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Subsidiary
- Established
- 1963-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.taiho.co.jp
Exploratory Study of TAC-302 in Detrusor Underactivity Patients With Overactive Bladder.
Phase 2
Completed
- Conditions
- Detrusor UnderactivityOveractive Bladder
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-06-05
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 195
- Registration Number
- NCT03175029
- Locations
- 🇯🇵
Taiho Pharmaceutical Co., Ltd selected site, Kumamoto, Japan
Exploratory Trial of TAS-303 in Female Patients With Stress Urinary Incontinence
- First Posted Date
- 2016-09-20
- Last Posted Date
- 2019-01-30
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 256
- Registration Number
- NCT02906683
- Locations
- 🇯🇵
Taiho Pharmaceutical Co., Ltd selected site, Osaka, Japan
A Phase IIa Study of TAS-205 for Duchenne Muscular Dystrophy
- First Posted Date
- 2016-04-26
- Last Posted Date
- 2020-04-20
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT02752048
- Locations
- 🇯🇵
Nagoya City University Hospital, Aichi, Japan
🇯🇵National Hospital Organization Nagara Medical Center, Gifu, Japan
🇯🇵National Hospital Organization Utano Hospital, Kyoto, Japan
A Study of TAS-303 in Female Patients With Stress Urinary Incontinence
Phase 1
Completed
- Conditions
- Stress Urinary Incontinence
- Interventions
- Drug: TAS-303 18mg single-doseDrug: TAS-303 9mg single-doseDrug: Placebo 18mg single-doseDrug: Placebo 9mg single-dose
- First Posted Date
- 2015-09-29
- Last Posted Date
- 2016-08-10
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT02562807
- Locations
- 🇯🇵
Taiho Pharmaceutical Co., Ltd selected site, Kumamoto, Japan
Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin in Patients With Advanced Gastric Cancer
Phase 3
Completed
- Conditions
- Gastric Cancer
- Interventions
- Drug: TAS-118 plus Oxaliplatin
- First Posted Date
- 2014-12-23
- Last Posted Date
- 2021-12-20
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 711
- Registration Number
- NCT02322593
- Locations
- 🇰🇷
Taiho Pharmaceutical Co., Ltd selected site, Seoul, Korea, Republic of
A Phase I Study of TAS-102 in Solid Tumors
- First Posted Date
- 2014-10-10
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 15
- Registration Number
- NCT02261532
- Locations
- 🇨🇳
Taiho Pharmaceutical Co., Ltd selected site, Beijing, China
A Study of TAS-205 for Duchenne Muscular Dystrophy
- First Posted Date
- 2014-09-22
- Last Posted Date
- 2021-06-04
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 23
- Registration Number
- NCT02246478
- Locations
- 🇯🇵
National Center of Neurology and Psychiatry, Tokyo, Japan
Study of Trifluridine/Tipiracil (TAS-102) in Patients With Metastatic Colorectal Cancer in Asia
- First Posted Date
- 2013-10-08
- Last Posted Date
- 2020-11-17
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 406
- Registration Number
- NCT01955837
- Locations
- 🇹ðŸ‡
Chulalongkorn University & The King Chulalongkorn Memorial Hospital, Bangkok, Thailand
🇨🇳Peking University Cancer Hospital, Beijing, China
🇰🇷Asan Medical Center, Seoul, Korea, Republic of
A Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Advanced Solid Tumors
- Interventions
- Drug: TAS-114 + S-1
- First Posted Date
- 2012-06-04
- Last Posted Date
- 2017-08-04
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT01610479
- Locations
- 🇯🇵
Site 01, Kashiwanoha, Kashiwa-shi, Chiba, Japan
Orantinib In Combination With Transcatheter Arterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma
Phase 3
Terminated
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Drug: Placebo
- First Posted Date
- 2011-11-04
- Last Posted Date
- 2019-08-07
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 888
- Registration Number
- NCT01465464
- Locations
- 🇨🇳
Local Institution, Taipei, Taiwan
© Copyright 2025. All Rights Reserved by MedPath